Sonay Kus Ozturk
Overview
Explore the profile of Sonay Kus Ozturk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kus Ozturk S, Bokhorst J, Baumann E, Sheahan K, van de Velde C, Marijnen C, et al.
Mod Pathol
. 2024 Nov;
38(2):100655.
PMID: 39522647
Owing to insufficient evidence, tumor budding (TB) is not currently evaluated in colorectal cancer (CRC) biopsies. This study investigates TB in CRC by establishing the value of intratumoral budding (ITB)...
2.
Dawson H, Bokhorst J, Studer L, Vieth M, Oguz Erdogan A, Kus Ozturk S, et al.
United European Gastroenterol J
. 2024 Jan;
12(3):299-308.
PMID: 38193866
Background: The International Collaboration on Cancer Reporting proposes histological tumour type, lymphovascular invasion, tumour grade, perineural invasion, extent, and dimensions of invasion as risk factors for lymph node metastases and...
3.
Kus Ozturk S, Graham Martinez C, Sheahan K, Winter D, Aherne S, Ryan E, et al.
Histopathology
. 2023 Aug;
83(6):870-879.
PMID: 37609761
Aims: Partial response to neoadjuvant chemoradiotherapy (CRT) presents with one of two main response patterns: shrinkage or fragmentation. This study investigated the relevance of these response patterns in rectal cancer,...
4.
Bokhorst J, Ciompi F, Kus Ozturk S, Oguz Erdogan A, Vieth M, Dawson H, et al.
Mod Pathol
. 2023 May;
36(9):100233.
PMID: 37257824
Tumor budding (TB), the presence of single cells or small clusters of up to 4 tumor cells at the invasive front of colorectal cancer (CRC), is a proven risk factor...
5.
Kus Ozturk S, Kirmizi A, Aras N, Ersoz C, Kurt Yuksel M, Unal Ince E, et al.
Turk J Gastroenterol
. 2023 Feb;
34(5):516-524.
PMID: 36806183
Background: The present study investigated gastrointestinal involvement patterns of acute graft-versus-host disease and assessed the correlation of pathologic severity with clinical grading. Methods: Pathology reports of gastrointestinal (GI) endoscopic biopsies...
6.
The immune microenvironment landscape shows treatment-specific differences in rectal cancer patients
Graham Martinez C, Barella Y, Kus Ozturk S, Ansems M, Gorris M, van Vliet S, et al.
Front Immunol
. 2022 Oct;
13:1011498.
PMID: 36238289
Neoadjuvant therapy is the cornerstone of modern rectal cancer treatment. Insights into the biology of tumor responses are essential for the successful implementation of organ-preserving strategies, as different treatments may...
7.
Graham Martinez C, Kus Ozturk S, Al-Kaabi A, Valkema M, Bokhorst J, Rosman C, et al.
Histopathology
. 2022 Mar;
80(6):982-994.
PMID: 35352847
Aims: No consensus exists on the clinical value of tumour regression grading (TRG) systems for therapy effects of neoadjuvant chemoradiotherapy (nCRT) in oesophageal adenocarcinoma. Existing TRG systems lack standardization and...
8.
Do the Well Known Prognostic Parameters in Pancreatic Ductal Adenocarcinoma Really Reflect Survival?
Kus Ozturk S, Erden E
Turk Patoloji Derg
. 2017 Oct;
34(2):127-133.
PMID: 28984346
Objective: Pancreatic ductal adenocarcinoma is an aggressive tumor with short survival. In this study we aimed to investigate the effect of well-known prognostic parameters on survival in these tumors. Material...